Literature DB >> 21828059

Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome.

Mingguo Huang1, Shintaro Narita, Norihiko Tsuchiya, Zhiyong Ma, Kazuyuki Numakura, Takashi Obara, Hiroshi Tsuruta, Mitsuru Saito, Takamitsu Inoue, Yohei Horikawa, Shigeru Satoh, Tomonori Habuchi.   

Abstract

Fibroblast growth factor-inducible 14 (Fn14), a transmembrane receptor binding to the multifunctional cytokine tumor necrosis factor-like weak inducer of apoptosis (TWEAK), is known to modulate many cellular activities including cancer progression. Here, we demonstrated the significant role of Fn14 in invasion, migration and proliferation of androgen-independent prostate cancer (AIPC) cells. Fn14 and its ligand TWEAK were highly expressed in two AIPC cell lines, DU 145 and PC-3, whereas expression was weak in androgen-sensitive LNCaP cells. Fn14 knockdown using small-interfering RNAs attenuated migration, invasion and proliferation and enhanced apoptosis in the AIPC cell lines. Both forced overexpression of Fn14 by stable Fn14 complementary DNA transfection to PC-3 cells (PC-3/Fn14) and ligand activation by recombinant TWEAK in PC-3 cells enhanced invasion. Fn14 was shown to modulate expression of matrix metalloproteinase (MMP)-9, and MMP-9 mediated the invasive potential influenced by Fn14 in PC-3 cells. In vivo, subcutaneous xenografts of PC-3/Fn14 grew significantly faster than xenograft of PC-3/Mock, and the invasive capacity in PC-3/Fn14 was found to be higher than that of PC-3/Mock as evaluated in an invasion model of the diaphragm. Furthermore, the messenger RNA expressions of MMP-9 in PC-3/Fn14 xenografts were significantly higher than those in PC-3/Mock xenografts. Clinically, high expression of Fn14 was significantly associated with higher prostate-specific antigen recurrence rate in patients who underwent radical prostatectomy. In conclusion, the overexpression of Fn14 may contribute to multiple malignant cellular phenotypes associated with prostate cancer (PCa) progression, in part via MMP-9. TWEAK-Fn14 signaling may be a novel therapeutic target of PCa.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21828059     DOI: 10.1093/carcin/bgr182

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  33 in total

Review 1.  The TWEAK-Fn14 system as a potential drug target.

Authors:  Harald Wajant
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

2.  Fn14 receptor promotes invasive potential and metastatic capacity of non-small lung adenocarcinoma cells through the up-regulation of integrin α6.

Authors:  J Jandova; C J Mason; S C Pawar; G S Watts
Journal:  Neoplasma       Date:  2015       Impact factor: 2.575

3.  Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC.

Authors:  Hong Zhou; Khalid A Mohamedali; Ana Maria Gonzalez-Angulo; Yu Cao; Mary Migliorini; Lawrence H Cheung; Janine LoBello; Xiudong Lei; Yuan Qi; Walter N Hittelman; Jeffrey A Winkles; Nhan L Tran; Michael G Rosenblum
Journal:  Mol Cancer Ther       Date:  2014-09-19       Impact factor: 6.261

4.  Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.

Authors:  Timothy G Whitsett; Emily Cheng; Landon Inge; Kaushal Asrani; Nathan M Jameson; Galen Hostetter; Glen J Weiss; Christopher B Kingsley; Joseph C Loftus; Ross Bremner; Nhan L Tran; Jeffrey A Winkles
Journal:  Am J Pathol       Date:  2012-05-23       Impact factor: 4.307

5.  The HER2- and heregulin β1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression.

Authors:  Kaushal Asrani; Ruth A Keri; Rebeca Galisteo; Sharron A N Brown; Sarah J Morgan; Arundhati Ghosh; Nhan L Tran; Jeffrey A Winkles
Journal:  Mol Cancer Res       Date:  2013-02-01       Impact factor: 5.852

Review 6.  The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics.

Authors:  J G Perez; N L Tran; M G Rosenblum; C S Schneider; N P Connolly; A J Kim; G F Woodworth; J A Winkles
Journal:  Oncogene       Date:  2015-08-24       Impact factor: 9.867

7.  Extracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancer.

Authors:  Bakhtiyor Yakubov; Bhadrani Chelladurai; Jordan Schmitt; Robert Emerson; John J Turchi; Daniela Matei
Journal:  Neoplasia       Date:  2013-06       Impact factor: 5.715

8.  Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors.

Authors:  Elaine T Lam; S Gail Eckhardt; Wells Messersmith; Antonio Jimeno; Cindy L O'Bryant; Ramesh K Ramanathan; Glen J Weiss; Manpreet Chadha; Abbie Oey; Han Ting Ding; Patricia A Culp; Stephan F Keller; Vivian Y Zhao; L Claire Tsao; Anil Singhal; Kyle D Holen; Daniel Von Hoff
Journal:  Mol Cancer Ther       Date:  2017-10-20       Impact factor: 6.261

9.  Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors.

Authors:  Hong Zhou; Walter N Hittelman; Hideo Yagita; Lawrence H Cheung; Stuart S Martin; Jeffrey A Winkles; Michael G Rosenblum
Journal:  Cancer Res       Date:  2013-05-30       Impact factor: 12.701

10.  AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis.

Authors:  JuanJuan Yin; Yen-Nien Liu; Heather Tillman; Ben Barrett; Stephen Hewitt; Kris Ylaya; Lei Fang; Ross Lake; Eva Corey; Colm Morrissey; Robert Vessella; Kathleen Kelly
Journal:  Cancer Res       Date:  2014-06-26       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.